Selinexor
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 100 patients (estimated)
- Sponsors
- University of Chicago Medicine
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 4 months ago
- SparkCures ID
- 636
- NCT Identifier
- NCT02199665
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.